{"Clinical Trial ID": "NCT00148668", "Intervention": ["INTERVENTION 1:", "1st arm", "- Herceptin/navelbine", "INTERVENTION 2:", "Second arm", "- Taxotere/carboplatin/herceptin"], "Eligibility": ["Incorporation criteria:", "Patients with Stage II or III breast cancer", "HER-2 positive tumours", "\u2022 Over 18 years of age", "Eastern Cooperative Oncology Group (ECOG) Performance Status greater than or equal to 1.", "ANC > 1500/mm3", "Hemoglobin > 9gm/dl", "Blisters > 100 000 mm3", "Creatinine < 2mg/dl", "Glucose < 200 mg/dl", "Bilirubine < 1.5 x ULN", "- Exclusion criteria:", "A prior treatment with herceptin, taxanes, doxorubicin or other anthracycline-type treatments, navelbine or platinum.", "Pregnant or lactating women", "A serious illness or a medical or psychiatric disorder", "Uncontrolled infections", "Active or serious cardiovascular or pulmonary diseases", "Patients with left ventricular ejection fraction < 50%", "- Peripheral neuropathy of any etiology greater than Class 1", "\u2022 History of malignancy", "- Uncontrolled diabetes"], "Results": ["Performance measures:", "\u00b7 Complete pathological response after preoperative treatment with Herceptin/Navellibine versus Taxotere/Carboplatin/Herceptin in patients with early positive breast cancer HER-2", "The complete pathological response is defined as the complete disappearance of the invasive tumour in the breast at the time of surgery.", "Time limit: 12 weeks", "Results 1:", "Title of arm/group: Arm 1", "Description of the arm/group: Herceptin/navelbine", "Total number of participants analysed: 41", "Type of measurement: Number", "Unit of measure: percentage of participants 17", "Results 2:", "Title of arm/group: Arm 2", "Description of the arm/group: Taxotere/carboplatin/herceptin", "Total number of participants analysed: 39", "Type of measurement: Number", "Unit of measure: percentage of participants 31"], "Adverse Events": ["Undesirable Events 1:", "Total: 5/41 (12.20 per cent)", "Neutropenia 4/41 (9.76%)", "Febrile Neutropenia 0/41 (0.00 %)", "- SGPT (ALT) 1/41 (2.44%)", "Adverse Events 2:", "Total: 5/40 (12.50 per cent)", "Neutropenia 4/40 (10.00 %)", "Febrile Neutropenia 1/40 (2.50%)", "- SGPT (ALT) 0/40 (0.00 %)"]}